-
More records set to fall as deadly Europe heatwave drags on
-
Israel's 'deliberate targeting' of children part of ongoing Gaza 'genocide': UN probe
-
England, Ghana eye last 32 as Portugal look for lift-off
-
Sri Lanka troops to battle deadly dengue mosquitoes as cases rise
-
Iran says to oversee Hormuz as Swiss talks conclude
-
Diaspora World Cup champions diversity over division
-
Guns, drones and doves: War reshapes Ukrainian jewellery scene
-
Australia withholds Pacific climate fund reports over risk of diplomatic 'damage'
-
Kenya police violence victims say compensation promise a 'smokescreen'
-
Indian startup head appointed as new WhatsApp boss
-
EU bets on digital euro to cut US tech addiction
-
Antetokounmpo joining Miami Heat in blockbuster: reports
-
Fineanganofo rethinks Newcastle move after All Blacks call-up
-
'Let's be realistic': Haaland cools Norway's World Cup expectations
-
Stocks fluctuate after Wall St sell-off, crude holds losses on peace talks
-
Lightning, downpour, a two-hour delay: bad weather hits the World Cup
-
Ultra-reclusive Turkmenistan slowly opens up to tourists
-
Two-goal Haaland fires Norway into World Cup last 32
-
Marc Bloch, historian and Resistance hero, joins France's Pantheon greats
-
Last one the best one? How Messi keeps doing it at World Cup
-
Ronaldo 'a role model' says Portugal coach after slow World Cup start
-
North Korea's Kim vows to accelerate military buildup
-
Savea 'embraces challlenge' of leading All Blacks towards World Cup
-
Latin America's resurgent right notches another win in Colombia
-
Mbappe scores twice as France beat Iraq at World Cup after two-hour storm delay
-
Trump threatens prison for damage to Washington Reflecting Pool
-
Shortages ease in Bolivia as protest roadblocks dismantled
-
World Cup exploits of Maradona and Messi have Argentina fans in raptures
-
FINOS Launches AI Fund to Amplify the Collective Voice of the Financial Services Industry and Accelerate Responsible Agentic AI Adoption
-
North America LiberNovo Prime Sale Fully Launches June 23
-
Empire Metals Limited Announces Investor Presentation on Investor Meet Company
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 23
-
Who Is Really Influencing Trump Marijuana Rescheduling?
-
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds
-
Star Copper Extends Copper Creek Drill Hole Beyond Planned Depth After Intersecting Mineralized System
-
England 'can beat any opponent' at World Cup, says Rice
-
'Boston Tea Party' compensation claim to be displayed at UK exhibit
-
Alvarez says 'best for everyone' if he leaves Atletico
-
France-Iraq World Cup game suspended due to severe weather alert
-
Romanian parliament rejects liberal PM-designate
-
Maduro ouster put Venezuela on 'the right path': interim leader
-
Missed penalty spurred 'very angry' Messi to World Cup history
-
Shooting in Montreal, Canada leaves three dead including suspect
-
Oil falls as US waives Iranian sanctions and Nasdaq tumbles
-
Balogun chases 'inevitable' Messi in wild Golden Boot race
-
Belgium's Doku becomes father after World Cup controversy
-
Magic Messi makes World Cup history to send Argentina into last 32
-
French TV presenter stood down over Doku World Cup comments
-
Ghana coach Queiroz says playing England 'easiest' World Cup game
-
Messi sets World Cup scoring record with 17th goal
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
O.Norris--AMWN